BetterLife Pharma Inc C.BETR

Alternate Symbol(s): BETRF

Healthcare

BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be self-administered. Its synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and is based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. It also owns a drug candidate for the treatment of viral infections.

CSE:BETR - Post by User

BetterLife Pharma Inc > BetterLife Pharma (BETR) let’s go.....

<< Previous

Bullboard Posts

Next >>

Post by mrBlockchainon Dec 18, 2020 3:25pm

260 Views

Post# 32141999

BetterLife Pharma (BETR) let’s go.....

Our new #1 favorite Psychstock for 2021 is Betterlife Pharma (CSE: BETR) or BETRF on the U.S. OTCQB. BETR is currently trading for $1.17 per share.

The psychedelic drug that Psychstocks Founder Gerard Adams believes has the biggest potential to effectively treat numerous mental health illnesses is LSD.

BETR has just acquired Transcend Biodynamics, which has its own patented process that allows for cost effective manufacturing of BOL-148, also known as 2-Bromo-LSD, without the need to make LSD. Transcend is the only entity with the ability to synthesize BOL-148 without the regulatory hurdles of handling a Schedule 1 controlled substance.

The patented process is known as "Process of synthesizing 2-bromo-LSD" and it was inventedby Justin Kirkland the CEO of BETR's newly acquired Transcend Biodynamics. BOL-148 is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potentialof LSD, without the hallucinations.

Gerard Adams is writing an in-depthPsychstocks report about BETR that he will publish next week. In addition, he will be profiling BETR in the final week of 2020 as his #1 psychedelic stock suggestion for 2021 to his NIA membership base.